Earlier diagnosis and earlier treatment of COPD in primary care

Primary Care Respiratory Journal

Volumn 20, Issue 1, 2011, Pages 15-22

  Price, David ^a   Freeman, Daryl ^a   Cleland, Jen ^a   Kaplan, Alan ^b   Cerasoli, Frank ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Family Physician Airways Group of Canada   (Canada)

^c PFIZER INC   (United States)

Author keywords

COPD; Early diagnosis; Early treatment; Primary care

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; LONG ACTING DRUG; PNEUMOCOCCUS VACCINE; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ASTHMA; BRONCHIECTASIS; BRONCHODILATATION; BRONCHUS CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; EXERCISE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HUMAN; INFLUENZA; LIFESTYLE; LUNG FUNCTION; MAINTENANCE THERAPY; PATIENT EDUCATION; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PREDICTION; PRIMARY MEDICAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SMOKING CESSATION; SPIROMETRY; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

EID: 85028109213     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2010.00060     Document Type: Review

References (74)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009 update. www.goldcopd.com. Last accessed 1-12-2009.
2. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009;64:863-868.
3. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006;61:1043-1047.http://dx.doi.org/ 10.1136/thx.2006.064410
4. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006; 43:75-80. http://dx.doi.org/10.1080/02770900500448738
5. Chang J, Mosenifar Z. Differentiating COPD from asthma in clinical practice. J Intensive Care Med 2007; 22:300-309.http://dx.doi.org/10.1177/0885066607304445
6. Zielinski J, Bednarek M, Gorecka D, et al. Increasing COPD awareness. Eur Respir J 2006;27:833-852.http://dx.doi.org/10.1183/09031936.06.00025905
7. Soriano JB, Ancochea J, Miravitlles M, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J 2009 [Epub ahead of print].
8. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653. http://dx.doi.org/10.1056/NEJMoa032158
9. Pratt PC, Kilburn KH. A modern concept of the emphysemas based on correlations of structure and function. Hum Pathol 1970;1:443-463.
10. Holme J, Stockley RA. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency. Chest 2007;132:909-915. http://dx.doi.org/10.1378/chest.07-0341
11. Omori H, Nakashima R, Otsuka N, et al. Emphysema detected by lung cancer screening with low-dose spiral CT: prevalence, and correlation with smoking habits and pulmonary function in Japanese male subjects. Respirology 2006; 11:205-210. http://dx.doi.org/10.1111/j.1440-1843.2006.00827.x
12. Wagena EJ, Kant I, van Amelsvoort LG, Wouters EF, van Schayck CP, Swaen GM. Risk of depression and anxiety in employees with chronic bronchitis: the modifying effect of cigarette smoking. Psychosom Med 2004;66:729-734. http://dx.doi.org/10.1097/01.psy.0000138127.00991.cf
13. Katz P, Julian L, Omachi TA, et al. The impact of disability on depression among individuals with COPD. Chest 2009;137:838-845.
14. Lindberg A, Larsson LG, Ronmark E, Jonsson AC, Larsson K, Lundback B. Decline in FEV1 in relation to incident chronic obstructive pulmonary disease in a cohort with respiratory symptoms. COPD 2007;4:5-13.
15. van der Molen T, Willemse BWM, Schokker S, Ten Hacken NHT, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:1-10. http://dx.doi.org/10.1186/1477-7525-1-13
16. Maleki-Yazdi MR, Lewczuk CK, Haddon JM, Choudry N, Ryan N. Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study. COPD 2007; 4:313-20.
17. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Resp J 2006; 15:346-353. http://dx.doi.org/10.1016/j.pcrj.2006.08.009
18. Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007; 101:1305-1312. http://dx.doi.org/10.1016/j.rmed.2006.10.012
19. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852. http://dx.doi.org/10.1136/thorax.57.10.847
20. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-708. http://dx.doi.org/10.1053/rmed.2002.1334
21. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006; 119:38-45. http://dx.doi.org/10.1016/j.amjmed.2006.08.006
22. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177:396-401. http://dx.doi.org/10.1164/rccm.200708-1290OC
23. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-1648.
24. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-390.
25. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823. http://dx.doi.org/10.1016/S0140-6736(98)10019-3
26. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-1953. http://dx.doi.org/10.1056/NEJM199906243402503
27. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
28. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554. http://dx.doi.org/10.1056/NEJMoa0805800
29. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009;374:1171-1178. http://dx.doi.org/10.1016/S0140-6736(09)61298-8
30. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-338. http://dx.doi.org/10.1164/rccm.200712-1869OC
31. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59.
32. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008;63:768-774. http://dx.doi.org/10.1136/thx.2007.093724
33. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166:675-679. http://dx.doi.org/10.1164/rccm.2112096
34. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest 2005;128:62-9. http://dx.doi.org/10.1378/chest.128.1.62
35. Spencer S, Calverley PMA, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128.
36. Price D, Crockett A, Arne M, et al. Spirometry in primary care caseidentification, diagnosis and management of COPD. Prim Care Resp J 2009; 18:216-223. http://dx.doi.org/10.4104/pcrj.2009.00055
37. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive ulmonary disease. Lancet 2009;374:721-732. http://dx.doi.org/10.1016/S0140-6736(09)61290-3
38. Levy ML, Fletcher M, Price DB, Hausen T, Halbert RJ, Yawn BP. International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Resp J 2006;15:20-34. http://dx.doi.org/10.1016/j.pcrj.2005.10.004
39. van den Boom G, van Schayck CP, Rutten-van Molken MPMH, et al. Active detection of chronic obstructive pulmonary diseas and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730-1738.
40. Zielinski J, Bednarek M. Know the Age of Your Lung Study Group. Early detection of COPD in a high-risk population using spirometric screening. Chest 2001;119:731-736. http://dx.doi.org/10.1378/chest.119.3.731
41. van den Boom G, Rutten-van Molken MP, Folgering H, van Weel C, van Schayck CP. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev Med 2000;30:302-308. http://dx.doi.org/10.1006/pmed.2000.0633
42. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. 2010 update. Available from: http://guidance.nice.org.uk/CG101. Last accessed 16 July 2010.
43. Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br J Gen Pract 2004;54:201-206.
44. Derom E, van Weel C, Liistro G, et al. Primary care spirometry. Eur Respir J 2008;31:197-203. http://dx.doi.org/10.1183/09031936.00066607
45. Lusuardi M, De Benedetto F, Paggiaro P, et al. A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. Chest 2006;129:844-852. http://dx.doi.org/10.1378/chest.129.4.844
46. Calverley PM, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D. Development of a population-based screening questionnaire for COPD. COPD 2005;2:225-232.
47. van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. Br Med J 2002; 324:1370-1374.
48. van Schayck C, Levy M, Chen J, Isonaka S, Halbert R. Coodinated diagnostic approach for adult obstructive lung disease in primary care. Prim Care Resp J 2004;13:218-221. http://dx.doi.org/10.1016/j.pcrj.2004.07.001
49. Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert RJ, for the COPD Questionnaire Study Group. Scoring system and clinical application of COPD diagnostic questionnaires. Chest 2006;129:1531-1539. http://dx.doi.org/10.1378/chest.129.6.1531
50. Freeman D, Nordyke RJ, Isonaka S, et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 2005;99:1311-1318. http://dx.doi.org/10.1016/j.rmed.2005.02.037
51. van Schayck CP, Halbert RJ, Nordyke RJ, Isonaka S, Maroni J, Nonikov D. Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting. Respirology 2005;10:323-333. http://dx.doi.org/10.1111/j.1440-1843.2005.00720.x
52. Price DB, Tinkelman DG, Halbert RJ, et al. Symptom-based questionnaire for identifying COPD in smokers. Respiration 2006;73:285-295. http://dx.doi.org/10.1159/000090142
53. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease -2008 update. Can Respir J 2008;15 Suppl A:1A-8A.
54. Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946. http://dx.doi.org/10.1183/ 09031936.04.00014304
55. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005;60:842-847. http://dx.doi.org/10.1136/thx.2005.043943
56. Tinkelman DG, Price DB, Nordyke RJ, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration 2006;73:296-305. http://dx.doi.org/10.1159/000090141
57. Hyland ME, Jones RC, Hanney KE. The Lung Information Needs Questionnaire: Development, preliminary validation and findings. Respir Med 2006;100:1807-1816. http://dx.doi.org/10.1016/j.rmed.2006.01.018
58. Anthonisen NR. Smoking, lung function, and mortality. Thorax 2000;55:729-734. http://dx.doi.org/10.1136/thorax.55.9.729
59. Pelkonen M, Tukiainen H, Tervahauta M, et al. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax 2000;55: 746-750. http://dx.doi.org/10.1136/thorax.55.9.746
60. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-817. http://dx.doi.org/10.1378/chest.127.3.809
61. Price D, Freeman D, Kaplan A, Ostrem A, Reid J, Molen T. Progressive breathlessness in COPD - the role of hyperinflation and its pharmacological management. Prim Care Resp J 2005;14:285-293. http://dx.doi.org/10.1016/j.pcrj.2005.08.005
62. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respir Res 2007;8:45 http://dx.doi.org/10.1186/1465-9921-8-45
63. Celli BR. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 2006;3:58-65. http://dx.doi.org/10.1513/pats.200510-111JH
64. Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. Pneumologie 2006;60:341-346. http://dx.doi.org/10.1055/s-2005-919145
65. Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Resp J 2008;17:169-175. http://dx.doi.org/10.3132/pcrj.2008.00037
66. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006;27:547-555. http://dx.doi.org/10.1183/09031936.06.00062705
67. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010 [Epub ahead of print].
68. Troosters T, Kesten S, Burkhart D, et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT trial. Am J Respir Crit Care Med 2009;179, A2467.
69. Crockett AJ, Price D. Co-morbid disease in COPD - more than a coincidence. Int J Chron Obstruct Pulmon Dis 2007;2:399-400.
70. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD 2008;5:235-256.
71. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-212. http://dx.doi.org/10.1183/09031936.00114307
72. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008;177:743-751. http://dx.doi.org/10.1164/rccm.200707-1011OC
73. Grabicki M, Parysek H, Batura-Gabryel H, Brodnicka I. Comorbidities as an element of multidimensional prognostic assessment of patients with chronic obstructive pulmonary disease. J Physiol Pharmacol 2008;59 Suppl 6:297-301.
74. Eickhoff P, Kiss D, Kohansal R, Valipour A, Geyer K, Burghuber C. Endothelial dysfunction in stable COPD - a link between systemic inflammation and cardiovascular morbidity? Eur Respir J 2006;28 Suppl 50:116s.